JANX
Janux TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
JANX Profile
Janux Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing immunotherapies for cancer
10955 Vista Sorrento Parkway, Suite 200, San Diego, California, 92130
--
Janux Therapeutics, Inc., was incorporated in Delaware on June 27, 2017. The Company is an innovative biopharmaceutical company developing next-generation therapies based on the Company's proprietary Tumor-Activated T-Cell Enginator (TRACTr) platform technology to better treat cancer patients. The company's initial focus is to develop a new class of T-cell adapters (TCE), and the company's main product candidates are designed for clinically validated drug targets.
